General Overview - The document outlines the management system for the shares held by the directors, senior management, and core technical personnel of Huaxi Biological Technology Co., Ltd. [1] Shareholding Management - The system is established in accordance with various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1] - It applies to the management of shares held by the company's directors, senior management, and core technical personnel [1] Trading Restrictions - Directors and senior management must be aware of laws prohibiting insider trading, market manipulation, and short-term trading before buying or selling shares [2] - They are prohibited from engaging in margin trading using the company's shares as the underlying security [2] Share Transfer Rules - There are specific circumstances under which shares held by directors and senior management cannot be transferred, including ongoing investigations or penalties related to securities violations [3] - Trading is restricted during certain periods, such as 15 days before the annual and semi-annual reports, and 5 days before quarterly reports [4] Reporting and Disclosure - The company secretary is responsible for managing the data and information regarding the shareholdings of directors and senior management, ensuring compliance with reporting requirements [11] - Any changes in shareholdings must be reported within two trading days, including details such as the number of shares held before and after the change [10] Penalties for Violations - Violations of the trading rules may result in the company recovering profits made from illegal trades and disclosing the situation publicly [12] - Serious violations can lead to penalties from the China Securities Regulatory Commission, including market bans for responsible individuals [13] Additional Provisions - The document specifies that any matters not covered will be governed by relevant national laws and regulations [14] - The management system will take effect upon approval by the company's board of directors, replacing any previous regulations [14]
华熙生物: 华熙生物科技股份有限公司董事、高级管理人员及核心技术人员所持本公司股份及其变动管理制度(2025年5月)